Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression
University of Calgary
452 participants
Feb 11, 2025
INTERVENTIONAL
Conditions
Summary
This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).
Eligibility
Inclusion Criteria4
- Age 12-17
- Depression and/or anxiety as the primary concern, confirmed by the treating physician
- Intention to start a new SSRI
- English fluency
Exclusion Criteria5
- Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
- History of non-response to 3 or more SSRI medications as confirmed by the treating physician
- Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
- History of liver or hematopoietic cell transplant
- History of CYP2B6, CYP2C19, or CYP2D6 testing
Interventions
SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
SSRI dosing based on current prescribing guidelines/recommendations
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06853587